"目录号: HY-14153A
GPCR/G ProteinNeuronal Signaling-
Tegaserod马来酸盐是5-HT4激动剂。
5-HT Receptor
相关产品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Aripiprazole-Ferulic acid sodium-Olanzapine-Sertindole-
生物活性
Description
Tegaserod maleate is a partial agonist of the 5-HT4 receptor; stimulates the peristaltic reflex and accelerates gastrointestinal transit.IC50 value:Target: 5-HT4 agonistIn an in vivo model for peripheral nerve regeneration, mice receiving tegaserod at the site of injury showed enhanced recovery compared to control mice receiving vehicle control as evidenced by functional measurements and histology [1]. Treatment with fluoxetine (10 mg · kg(-1) · day(-1), days 36-42), tegaserod (1 mg · kg(-1) · day(-1), day 43), or the combination of both, reduced visceral hypersensitivity and plasma 5-HT levels [2]. Intravenous or intraduodenal tegaserod (0.3-1.0 mg.kg(-1)) had no inhibitory effect on mesenteric and colonic blood flow. Peroral treatment of rats with alosetron or tegaserod for 7 days did not modify mesenteric haemodynamics at baseline and after blockade of nitric oxide synthesis [3].
Clinical Trial
NCT00511771
Novartis
Irritable Bowel Syndrome With Constipation-Chronic Idiopathic Constipation
NCT00277550
Novartis-Mayo Clinic
Constipation and Dyspepsia
Phase 4
NCT00399659
Novartis
Opioid-induced Constipation
November 2006
Phase 3
NCT00414024
Novartis
Opioid-induced Constipation
February 2007
Phase 3
NCT00390975
Novartis
Gastroparesis-Diabetes
January 2007
Phase 4
NCT00149877
Novartis
Chronic Constipation
April 2004
Phase 4
NCT00171457
Novartis
Heartburn-Dyspepsia
April 2005
Phase 3
NCT00171470
Novartis
Dyspepsia
April 2005
Phase 3
NCT00232102
Novartis
Dyspepsia
September 2004
Phase 3
NCT00232037
Novartis
Dyspepsia
September 2004
Phase 3
NCT00141089
Novartis
Chronic Constipation
March 2004
Phase 3
NCT00348634
Novartis-Temple University-University of Michigan
Chronic Constipation
July 2006
Phase 4
NCT00171522
Novartis
Constipation
May 2005
Phase 4
NCT00171483
Novartis
Gastroesophageal Reflux Disease (GERD)
January 2004
Phase 3
NCT00142974
Novartis
Diabetic Gastropathy
May 2004
Phase 2
NCT00142987
Novartis
IBS-C and IBS With Mixed Bowel Habits
April 2004
Phase 4
NCT00232089
Novartis
Dyspepsia
May 2004
Phase 3
NCT00232024
Novartis
Dyspepsia
January 2004
Phase 3
NCT00171431
Novartis Pharmaceuticals-Novartis
Constipation Predominant-Irritable Bowel Syndrome (IBS-C)
November 2004
Phase 3
NCT00171418
Novartis
Gastroesophageal Reflux Disease (GERD)
June 2003
Phase 3
NCT00365820
Novartis
Constipation
July 2006
Phase 2-Phase 3
NCT00139568
Novartis
Constipation
February 2005
Phase 3
NCT00563615
Hospital Authority, Hong Kong-Novartis Pharmaceuticals
Constipation
November 2004
NCT00563758
Hospital Authority, Hong Kong-Novartis
Constipation-Chronic Disease
December 2004
NCT00149851
Novartis
Symptomatic Gastroespohageal Reflux Disease
January 2004
Phase 2
View MoreCollapse
References
[1].Bushman J, et al. Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair. Neuropharmacology. 2014 Apr;79:456-66.
[2].Yan C, et al. Effect of the 5-HT4 receptor and serotonin transporter on visceral hypersensitivity in rats. Braz J Med Biol Res. 2012 Oct;45(10):948-54.
[3].Painsipp E, et al. Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. Br J Pharmacol. 2009 Nov;158(5):1210-26.